Given the repeated failures of trials targeting the Aβ pathway in mild or moderate AD [53], there is increasing interest in the possibility that tau-targeted compounds could have therapeutic utility in AD, particularly tau aggregation inhibitors. This evidence concerns the gene MAPT and Alzheimer disease.